JUN and urinary bladder carcinoma: Moreover, Sestrin2 is known to be downregulated in bladder cancer, and when Sestrin2 is induced in response to mitogen-activated protein kinase 8 (MAPK8)-JUN)-dependent transcription, it suppresses bladder cancer growth [23].